Additional data from ALS individuals signed up for confirmatory Phase III Celebrity trial announced AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis signed up for the confirmatory Phase III STAR trial dmae benefits . In the ALS patient subset, both Zenvia 30/10 mg and Zenvia 20/10 mg met significantly the principal efficacy endpoint by reducing daily PBA show rates in comparison to placebo . These results were presented today throughout a podium presentation at the 20th International Symposium on ALS/MND in Berlin, Germany.0001 for both treatment groups) Both Zenvia groups fulfilled the secondary endpoint in the subset of patients with underlying ALS by considerably reducing mean CNS-LS scores compared to placebo> Zenvia was secure and well-tolerated in the ALS individual subset generally Reported that 90.8 percent, 77.9 percent and 85.

Additional data about safety, tolerability of Cempra’s solithromycin to be presented at 51st ICAAC Cempra Pharmaceuticals today announced abstracts to end up being presented on its 4th generation macrolide and novel fluoroketolide antibiotic, solithromycin , at the 51st Interscience Conference on Antimicrobial Brokers and Chemotherapy , September 17 to 20, 2011, in Chicago. The compound has potent in vitro activity against respiratory pathogens such as for example pneumococci, including macrolide – and quinolone-resistant strains.